This report describes and explains the hemoglobin A1c (HbA1c) testing market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global hemoglobin A1c (HbA1c) testing market reached a value of nearly $1.86 billion in 2024, having grown at a compound annual growth rate (CAGR) of 5.73% since 2019. The market is expected to grow from $1.86 billion in 2024 to $2.89 billion in 2029 at a rate of 9.22%. The market is then expected to grow at a CAGR of 9.14% from 2029 and reach $4.48 billion in 2034.
Growth in the historic period resulted from the increasing focus on personalized medicine, rising prevalence of diabetes, rise in obesity rates and government initiatives. Factors that negatively affected growth in the historic period were high cost of testing devices and reagents.
Going forward, strong economic growth in emerging markets, rising healthcare expenditures, increasing urbanization and expanding geriatric population will drive the growth. Factor that could hinder the growth of the hemoglobin A1c (HbA1c) testing market in the future include lack of trained healthcare professionals.
The global hemoglobin A1c (HbA1c) testing market is fairly fragmented, with a large number of players operating in the market. The top ten competitors in the market made up 18.1% of the total market in 2023. Danaher Corporation (Beckman Coulter, Inc.) was the largest competitor with a 6.5% share of the market, followed by F. Hoffmann-La Roche Ltd. with 2.4%, Siemens Healthineers AG with 2.2%, Abbott Laboratories with 1.5%, Bio-Rad Laboratories, Inc. with 1.4%, Randox Laboratories Ltd. with 1.3%, Thermo Fisher Scientific Inc. with 1%, Sysmex Corporation with 0.9%, ARKRAY Inc. with 0.6% and Tosoh Corporation with 0.3%.
The hemoglobin A1c (HbA1c) testing market is segmented by type into laboratory-based testing and point of care (PoC) testing. The point of care (PoC) testing market was the largest segment of the hemoglobin A1c (HbA1c) testing market segmented by type, accounting for 78.15% or $1.45 billion of the total in 2024. Going forward, the point of care (PoC) testing segment is expected to be the fastest growing segment in the hemoglobin A1c (HbA1c) testing market segmented by type, at a CAGR of 9.62% during 2024-2029.
The hemoglobin A1c (HbA1c) testing market is segmented by product type into reagents and kits, instruments and software and services. The reagents and kits market was the largest segment of the hemoglobin A1c (HbA1c) testing market segmented by product type, accounting for 61.08% or $1.13 billion of the total in 2024. Going forward, the software and services segment is expected to be the fastest growing segment in the hemoglobin A1c (HbA1c) testing market segmented by product type, at a CAGR of 11.24% during 2024-2029.
The hemoglobin A1c (HbA1c) testing market is segmented by technology into immunoassays, chromatography, enzymatic assays, boronate affinity chromatography, high performance liquid chromatography and other technologies. The immunoassays market was the largest segment of the hemoglobin A1c (HbA1c) testing market segmented by technology, accounting for 36.42% or $678.57 million of the total in 2024. Going forward, the high-performance liquid chromatography segment is expected to be the fastest growing segment in the hemoglobin A1c (HbA1c) testing market segmented by technology, at a CAGR of 12.61% during 2024-2029.
The hemoglobin A1c (HbA1c) testing market is segmented by end user into hospitals and clinics, diagnostic laboratories, homecare settings and other end users. The hospitals and clinics market was the largest segment of the hemoglobin A1c (HbA1c) testing market segmented by end user, accounting for 40.91% or $762.26 million of the total in 2024. Going forward, the homecare settings segment is expected to be the fastest growing segment in the hemoglobin A1c (HbA1c) testing market segmented by end user, at a CAGR of 13.02% during 2024-2029.
North America was the largest region in the hemoglobin A1c (HbA1c) testing market, accounting for 42.60% or $793.76 million of the total in 2024. It was followed by Asia-Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the hemoglobin A1c (HbA1c) testing market will be Asia-Pacific and South America where growth will be at CAGRs of 10.80% and 10.63% respectively. These will be followed by Middle East and Africa where the markets are expected to grow at CAGRs of 9.83% and 9.54% respectively.
The top opportunities in the hemoglobin A1c (HbA1c) testing market segmented by type will arise in the point of care (PoC) testing segment, which will gain $848.4 million of global annual sales by 2029. The top opportunities in the hemoglobin A1c (HbA1c) testing market segmented by product type will arise in the reagents and kits segment, which will gain $661.73 million of global annual sales by 2029. The top opportunities in the hemoglobin A1c (HbA1c) testing market segmented by technology will arise in the immunoassays segment, which will gain $344.4 million of global annual sales by 2029. The top opportunities in the hemoglobin A1c (HbA1c) testing market segmented by end user will arise in the diagnostic laboratories segment, which will gain $403.19 million of global annual sales by 2029. The hemoglobin A1c (HbA1c) testing market size will gain the most in USA at $320.94 million.
Market-trend-based strategies for the hemoglobin A1c (HbA1c) testing market include launch of next-generation point-of-care device enhances diabetes management and early diagnosis, empowering health with at-home diabetes risk (HbA1c) collection kits, advancements in testing with focus on high-performance liquid chromatography (HPLC) analyzers for enhanced diabetes management and innovations in hemoglobin A1c (HbA1c) testing using menstrual blood.
Player-adopted strategies in the hemoglobin A1c (HbA1c) testing market include focus on enhancing its operational capabilities through strategic acquisitions, business operations through new launches and operational capabilities through strategic partnerships.
To take advantage of the opportunities, the analyst recommends the hemoglobin A1c (HbA1c) testing companies to focus on next-generation point-of-care devices for HbA1c testing, focus on at-home HbA1c testing solutions, focus on high-performance liquid chromatography analyzers for HbA1c testing, focus on enhanced point-of-care testing for HbA1c, focus on point-of-care testing for HbA1c, focus on software and services for HbA1c testing, focus on high performance liquid chromatography for HbA1c testing, focus on software and services for HbA1c testing, expand in emerging markets, continue to focus on developed markets, provide competitively priced offerings, continue to use B2C promotions, participate in trade shows and events, focus on homecare settings for HbA1c testing and focus on targeting urban populations for HbA1c testing.
The global hemoglobin A1c (HbA1c) testing market reached a value of nearly $1.86 billion in 2024, having grown at a compound annual growth rate (CAGR) of 5.73% since 2019. The market is expected to grow from $1.86 billion in 2024 to $2.89 billion in 2029 at a rate of 9.22%. The market is then expected to grow at a CAGR of 9.14% from 2029 and reach $4.48 billion in 2034.
Growth in the historic period resulted from the increasing focus on personalized medicine, rising prevalence of diabetes, rise in obesity rates and government initiatives. Factors that negatively affected growth in the historic period were high cost of testing devices and reagents.
Going forward, strong economic growth in emerging markets, rising healthcare expenditures, increasing urbanization and expanding geriatric population will drive the growth. Factor that could hinder the growth of the hemoglobin A1c (HbA1c) testing market in the future include lack of trained healthcare professionals.
The global hemoglobin A1c (HbA1c) testing market is fairly fragmented, with a large number of players operating in the market. The top ten competitors in the market made up 18.1% of the total market in 2023. Danaher Corporation (Beckman Coulter, Inc.) was the largest competitor with a 6.5% share of the market, followed by F. Hoffmann-La Roche Ltd. with 2.4%, Siemens Healthineers AG with 2.2%, Abbott Laboratories with 1.5%, Bio-Rad Laboratories, Inc. with 1.4%, Randox Laboratories Ltd. with 1.3%, Thermo Fisher Scientific Inc. with 1%, Sysmex Corporation with 0.9%, ARKRAY Inc. with 0.6% and Tosoh Corporation with 0.3%.
The hemoglobin A1c (HbA1c) testing market is segmented by type into laboratory-based testing and point of care (PoC) testing. The point of care (PoC) testing market was the largest segment of the hemoglobin A1c (HbA1c) testing market segmented by type, accounting for 78.15% or $1.45 billion of the total in 2024. Going forward, the point of care (PoC) testing segment is expected to be the fastest growing segment in the hemoglobin A1c (HbA1c) testing market segmented by type, at a CAGR of 9.62% during 2024-2029.
The hemoglobin A1c (HbA1c) testing market is segmented by product type into reagents and kits, instruments and software and services. The reagents and kits market was the largest segment of the hemoglobin A1c (HbA1c) testing market segmented by product type, accounting for 61.08% or $1.13 billion of the total in 2024. Going forward, the software and services segment is expected to be the fastest growing segment in the hemoglobin A1c (HbA1c) testing market segmented by product type, at a CAGR of 11.24% during 2024-2029.
The hemoglobin A1c (HbA1c) testing market is segmented by technology into immunoassays, chromatography, enzymatic assays, boronate affinity chromatography, high performance liquid chromatography and other technologies. The immunoassays market was the largest segment of the hemoglobin A1c (HbA1c) testing market segmented by technology, accounting for 36.42% or $678.57 million of the total in 2024. Going forward, the high-performance liquid chromatography segment is expected to be the fastest growing segment in the hemoglobin A1c (HbA1c) testing market segmented by technology, at a CAGR of 12.61% during 2024-2029.
The hemoglobin A1c (HbA1c) testing market is segmented by end user into hospitals and clinics, diagnostic laboratories, homecare settings and other end users. The hospitals and clinics market was the largest segment of the hemoglobin A1c (HbA1c) testing market segmented by end user, accounting for 40.91% or $762.26 million of the total in 2024. Going forward, the homecare settings segment is expected to be the fastest growing segment in the hemoglobin A1c (HbA1c) testing market segmented by end user, at a CAGR of 13.02% during 2024-2029.
North America was the largest region in the hemoglobin A1c (HbA1c) testing market, accounting for 42.60% or $793.76 million of the total in 2024. It was followed by Asia-Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the hemoglobin A1c (HbA1c) testing market will be Asia-Pacific and South America where growth will be at CAGRs of 10.80% and 10.63% respectively. These will be followed by Middle East and Africa where the markets are expected to grow at CAGRs of 9.83% and 9.54% respectively.
The top opportunities in the hemoglobin A1c (HbA1c) testing market segmented by type will arise in the point of care (PoC) testing segment, which will gain $848.4 million of global annual sales by 2029. The top opportunities in the hemoglobin A1c (HbA1c) testing market segmented by product type will arise in the reagents and kits segment, which will gain $661.73 million of global annual sales by 2029. The top opportunities in the hemoglobin A1c (HbA1c) testing market segmented by technology will arise in the immunoassays segment, which will gain $344.4 million of global annual sales by 2029. The top opportunities in the hemoglobin A1c (HbA1c) testing market segmented by end user will arise in the diagnostic laboratories segment, which will gain $403.19 million of global annual sales by 2029. The hemoglobin A1c (HbA1c) testing market size will gain the most in USA at $320.94 million.
Market-trend-based strategies for the hemoglobin A1c (HbA1c) testing market include launch of next-generation point-of-care device enhances diabetes management and early diagnosis, empowering health with at-home diabetes risk (HbA1c) collection kits, advancements in testing with focus on high-performance liquid chromatography (HPLC) analyzers for enhanced diabetes management and innovations in hemoglobin A1c (HbA1c) testing using menstrual blood.
Player-adopted strategies in the hemoglobin A1c (HbA1c) testing market include focus on enhancing its operational capabilities through strategic acquisitions, business operations through new launches and operational capabilities through strategic partnerships.
To take advantage of the opportunities, the analyst recommends the hemoglobin A1c (HbA1c) testing companies to focus on next-generation point-of-care devices for HbA1c testing, focus on at-home HbA1c testing solutions, focus on high-performance liquid chromatography analyzers for HbA1c testing, focus on enhanced point-of-care testing for HbA1c, focus on point-of-care testing for HbA1c, focus on software and services for HbA1c testing, focus on high performance liquid chromatography for HbA1c testing, focus on software and services for HbA1c testing, expand in emerging markets, continue to focus on developed markets, provide competitively priced offerings, continue to use B2C promotions, participate in trade shows and events, focus on homecare settings for HbA1c testing and focus on targeting urban populations for HbA1c testing.
Major Market Trends
- Launch of Next-Generation Point-of-Care Device Enhances Diabetes Management and Early Diagnosis
- Empowering Health With At-Home Diabetes Risk (HbA1c) Collection Kits
- Advancements in Testing With Focus on High-Performance Liquid Chromatography (HPLC) Analyzers for Enhanced Diabetes Management
- Innovations in Hemoglobin A1c (HbA1c) Testing Using Menstrual Blood
Key Mergers and Acquisitions
- Roche Holding AG Acquired LumiraDx to Enhance Primary Care Diagnostics
- Tosoh Corporation Acquired Semba Biosciences Inc. to Enhance Biologics Purification and HbA1c Testing
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Major Market Trends
8 Hemoglobin A1c (HbA1c) Testing Market - Macro Economic Scenario
9 Global Market Size and Growth
10 Global Hemoglobin A1c (HbA1c) Testing Volume
11 Global Hemoglobin A1c (HbA1c) Testing Market Segmentation
12 Hemoglobin A1c (HbA1c) Testing Market, Regional and Country Analysis
13 Asia-Pacific Market
14 Western Europe Market
15 Eastern Europe Market
16 North America Market
17 South America Market
18 Middle East Market
19 Africa Market
20 Competitive Landscape and Company Profiles
21 Other Major and Innovative Companies
24 Key Mergers and Acquisitions
25 Opportunities and Strategies
26 Hemoglobin A1c (HbA1c) Testing Market, Conclusions and Recommendations
27 Appendix
Executive Summary
Hemoglobin A1c (HbA1c) Testing Global Market Opportunities and Strategies to 2034 provides the strategists; marketers and senior management with the critical information they need to assess the global hemoglobin A1c (HbA1c) testing market as it emerges from the COVID-19 shut down.Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for hemoglobin A1c (HbA1c) testing? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The hemoglobin A1c (HbA1c) testing market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider hemoglobin A1c (HbA1c) testing market; and compares it with other markets.
The report covers the following chapters:
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by product type, by technology and by end user.
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Macro-Economic Scenario - the report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the hemoglobin A1c (HbA1c) testing market.
- Global Market Size and Growth Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional and Country Analysis Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
- Market Segmentation Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type, by product type, by technology and by end user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Regional Market Size and Growth Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major and Innovative Companies Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
- Competitive Dashboard - Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Opportunities and Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions and Recommendations - This section includes recommendations for hemoglobin A1c (HbA1c) testing providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) by Type: Laboratory Based Testing; Point of Care (PoC) Testing2) by Product Type: Reagents and Kits; Instruments; Software and Services
3) by Technology: Immunoassays; Chromatography; Enzymatic Assays; Boronate Affinity Chromatography; High Performance Liquid Chromatography; Other Technologies
4) by End User: Hospitals and Clinics; Diagnostic Laboratories; Homecare Settings; Other End Users
Key Companies Mentioned: Danaher Corporation (Beckman Coulter, Inc.); F. Hoffmann-La Roche Ltd.; Siemens Healthineers AG; Abbott Laboratories; Bio-Rad Laboratories, Inc.
Countries: China; Australia; India; Indonesia; Japan; South Korea; Thailand; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; hemoglobin A1c (HbA1c) testing indicators comparison.
Data Segmentation: Country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
Some of the major companies featured in this Hemoglobin A1c (HbA1c) Testing market report include:- Danaher Corporation (Beckman Coulter, Inc.)
- F. Hoffmann-La Roche Ltd.
- Siemens Healthineers AG
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- Randox Laboratories Ltd.
- Thermo Fisher Scientific Inc.
- Sysmex Corporation
- ARKRAY Inc.
- Tosoh Corporation
- Osang HealthCare Co. Ltd
- PTS Diagnostics
- bioMérieux
- Rapid Diagnostic Pvt. Ltd
- Agappe Diagnostic Ltd
- Transasia Bio-Medicals Ltd.
- Nipro Corp
- Sekisui Medical Co. Ltd
- HemoCue AB
- Achira Labs Pvt. Ltd
- AccuBioTech Co., Ltd
- Molbio Diagnostics Pvt. Ltd.
- Cipla Limited
- Lepu Medical Technology (Beijing) Co. Ltd.
- Randox Laboratoris
- Trinity Biotech PLC
- EKF Diagnostics
- Eurolyser Diagnostica GmbH
- Bayer AG
- A. Menarini Diagnostics S.r.l.
- Agappe Diagnostics Ltd
- Biorex Diagnostics
- DiaSys Diagnostic Systems GmbH
- Synevo
- Medicover
- Beckman Coulter, Inc.
- Regina Maria
- Diabetes Medica
- Qvin
- ACON Laboratories
- Labcorp
- Diazyme Laboratories
- Alere
- Truvian Health
- Nova Biomedical Corporation
- Grupo Biolab
- AstraZeneca
- Ortho Clinical Diagnostics
- BioTeknica
- Ascensia
- Trinity Biotech
- Huma
- Kainico Ltd.
- Agamatrix Inc.
- Bionime Corporation
- lifeScan IP Holdings
- B Braun Melsungen AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 312 |
| Published | February 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 1.86 Billion |
| Forecasted Market Value ( USD | $ 4.48 Billion |
| Compound Annual Growth Rate | 9.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 58 |
